| Literature DB >> 34331571 |
Pierluigi Bonomo1, Giulia Stocchi2, Saverio Caini3, Isacco Desideri2, Veronica Santarlasci4, Carlotta Becherini2, Vittorio Limatola4, Luca Giovanni Locatello5, Giuditta Mannelli6, Giuseppe Spinelli7, Carmelo Guido8, Lorenzo Livi2.
Abstract
PURPOSE: In head and neck squamous cell carcinoma (HNSCC), the potential mitigating effect of complementary medicine interventions such as acupuncture for radiation-induced toxicity is unknown. This study aimed to assess the impact of acupuncture on the incidence and degree of severity of common radiation-induced side effects.Entities:
Keywords: Acupuncture; Chemotherapy; Head and neck cancer; Radiotherapy; Toxicity
Mesh:
Year: 2021 PMID: 34331571 PMCID: PMC8930866 DOI: 10.1007/s00405-021-07002-1
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
Fig. 1Flow chart of literature search
Study design and patient characteristics
| Author [ref] | Year | Study design | Patients (total) | Setting | Patients (treated with TA) | Patients (treated with SA) | Patients (treated with SC) | Age, years (mean) | Age, years (range) | Male no. (%) | Female no. (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Braga F et al. [ | 2011 | Prospective cohort study | 24 | single center | 12 | 0 | 12 | 63 | 44–82 | 16 (66.7) | 8 (33.3) |
| Meng Z et al. [ | 2012 | Randomized phase 2 study | 84 | single center | 39 | 0 | 45 | 47.2 | ns | 59 (70.2) | 25 (29.8) |
| Simcock R et al. [ | 2013 | Randomized crossover phase 3 study | 144 | multicenter (7) | 144a | 0 | 144a | 59.4 | 41–83 | 109 (75.7) | 35 (24.3) |
| Lu W et al. [ | 2016 | Randomized phase 2 study | 42 | multicenter (2) | 21 | 21 | 0 | 58.1 | ns | 34 (80.9) | 8 (19.1) |
| Garcia MK et al. [ | 2019 | Randomized phase 3 study | 339° | multicenter (2) | 112 | 115 | 112 | 51.3 | 21–79 | 258 (77.6) | 81 (22.4) |
339 patients were included in the final analysis out of 399 randomized subjects
TA true acupuncture, SA sham acupuncture, SC standard care
a74 patients were randomized to oral care followed by TA, whereas 70 to TA followed by oral care
Fig. 2Quality assessment according to the Cochrane review tool. TA true acupuncture; SA sham acupuncture; SC standard care
Disease features
| Author [ref] | Year | Patients | Primary tumor site | Disease stage | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral cavity | Oropharynx | Larynx | Hypopharynx | Nasopharynx | Other/unknown | I | II | III | IV | |||
| Braga F et al. [ | 2011 | 24 | 5 (20.8) | 3 (12.5) | 7 (29.2) | 4 (16.7) | 1 (4.1) | 4 (16.7) | ns | ns | ns | ns |
| Meng Z et al. [ | 2012 | 84 | 0 | 0 | 0 | 0 | 84 (100) | 0 | 5 (5.9) | 27 (32.2) | 34 (40.5) | 18 (21.4) |
| Simcock R et al. [ | 2013 | 144 | 11 (7.7) | 100 (69.4) | 9 (6.2) | 6 (4.2) | 6 (4.2) | 12 (8.3) | nsa | ns | ns | ns |
| Lu W et al. [ | 2016 | 42 | 1 (2.4) | 30 (71.4) | 2 (4.8) | 1 (2.4) | 2 (4.8) | 6 (14.2) | 1 (2.4) | 0 | 5 (11.9) | 36 (85.7) |
| Garcia MK et al. [ | 2019 | 358a | 0 | 137 (38.3) | 0 | 0 | 221 (61.7) | 0 | 11 (3) | 37 (10.4) | 118 (33) | 192 (53.6) |
ns not stated
aIncludes all participants with baseline data plus at least 1 follow-up at any time
bOnly separate T and N data, no information on stage
Treatment and acupuncture features
| Author [ref] | Patients | RT technique | RT total dose (mean, Gy) | Dose | Induction CT (n, %) | Concurrent CT (n, %) | Timing of acupuncture | Acupuncture sessions (n) | Acupoints protocol |
|---|---|---|---|---|---|---|---|---|---|
| Braga F et al. [ | TA: 12 SC: 12 | 2D (all) | 67.7 68.1 | RT fields involved > 50% of major salivary glands (all) | / | 4/12 (33.3) 7/12 (58.3) | before and during RT, twice a week | 16–20 | ST-3, ST-4, ST-5, ST-6, ST-7, GB-2, SI-19, TB-21, LI-4, LI-11, LR-3, ST-26, KI-3, KI-5, GV 20, Shen-Men, Centra Nervous System, Kidney, Spleen, Pancreas, Mouth 14 bilaterally + GV-20 (29 acupoints for session) |
| Meng Z et al. [ | TA: 39 SC: 45 | 3DCRT (all) | 70.8 70.9 | no data provided | 41/84 (48.8) | 39/84 (46.4) | During RT, 3 times a week | 21 | Ren-24, Lung-7, Kidney-6, Shen-Men, Point Zero, Salivary Gland 2’, Larynx 6 bilaterally + Ren-24 (13 acupoints for session) |
| Simcock R et al. [ | Oral care-TA: 74 TA-oral care: 70 | 2D/3D: 143 IMRT: 1 (all) | 63.5 65.6 | At least 1 parotid gland in the irradiated field (all) | /a | 46/74 (62.1) 48/70 (68.5) | After RT, disease free-interval ≥ 18 months; once a week | 8 | Salivary Gland 2’, Modified Point Zero, Shen-Men, LI-2, LI-20 6 bilaterally (12 acupoints for session) |
| Lu W et al. [ | TA: 21 SA: 21 | IMRT (all) | 69.2 68.7 | no data provided | /a | 42/42 (100) | During and after RT, starting 2 weeks into RT up to 20 weeks after it; once every 2 weeks | 12 | ST7, ST6, ST5, GB20, SI16, CV23, LI11, LI2, SP9, K3, ST36, SP6, GV20, GV24, Yintang, CV24 12 bilaterally (28 acupoints for session) |
| Garcia MK et al. [ | TA: 118b SA: 124 SC: 116 | IMRT (all) | 66–70.4 (prescribed dose; all) | 78: PGs > 26 Gyc (66) 79: PGs > 26 Gyc (63) 79: PGs > 26 Gyc (68) | 69/118 (58) 77/124 (62) 72/116 (62) | 86/118 (72.8) 91/124 (73.3) 81/116 (69.8) | During RT, 3 times a week | 18–21 | Salivary Gland 2’, Shen-Men, Point Zero, Larynx, LU7, K6, GB32, Ren-24 6 bilaterally (14 acupoints for session) |
RT radiotherapy, Gy Gray, OAR’s organs at risk, CT chemotherapy, TA true acupuncture, SA sham acupuncture, SC standard care, 2D 2-dimensional radiotherapy, 3DCRT 3-D conformal radiotherapy, IMRT intensity modulated radiotherapy, PGs parotid glands
aUnspecified as whether chemotherapy was given before, concomitantly to radiation, or both
bIncludes all participants with baseline data plus at least 1 follow-up at any time (358)
cMean dose
Impact of acupuncture on radiation-induced toxicity, qualitative analysis
| Author [ref] | Patients | Primary endpoint | Assessment | Main secondary endpoint | Assessment | Efficacy size | Main message |
|---|---|---|---|---|---|---|---|
| Braga F et al. [ | TA: 12 SC: 12 | RSFR SSFR | Last day of RT (mixed model procedure with random and fixed factors; ANOVA) | Patient-reported xerostomia through a modified xerostomia questionnaire (4-item VAS) | Last day of RT (mixed model procedure with random and fixed factors; ANOVA) | Primary: mean RSFR, 0.21 vs 0.04 mL/min; mean SSFR, 0.49 vs 0.12 mL/min ( Secondary: mean scores of 4-item VAS lower (Q1, Q2, Q4) and higher (Q3) with TA ( | Improved objective sialometry measures and decreased xerostomia-related symptoms at RT completion: preventive effect of TA on acute toxicity |
| Meng Z et al. [ | TA: 39 SC: 45 | Patient-reported xerostomia through Xerostomia Questionnaire (8-item) | 1 and 6 months after RT (SAS PROC MIXED, linear mixed models; chi square-analyses) | RSFR SSFR | 1 and 6-months after RT (SAS PROC MIXED, linear mixed models; analysis of covariance) | Primary: @1 month, 54.3%vs 86.1% of patients had XQ > 30 (RR 0.63; 95% CI 0.45–9.87, @6 months, 24.1% vs 63.6% of patients had XQ > 30 (RR 0.38; 95% CI 0.19–0.76, Secondary: SSFR @6 months of 1.57 vs 0.95, group difference 0.62; 95% CI 0.22–1.01, | Improved patient-reported severe xerostomia and time-trend effect on SSFR: preventive effect of TA on acute and early late (6-month) toxicity |
| Simcock R et al. [ | Oral care-TA: 74 TA-oral care: 70 | Patient-reported xerostomia through EORTC H&N 35 + 4 study-specific items | 3 and 6 months after TA (logistic regression models) | Global QoL score RSFR SSFR | 3 and 6 months after TA (logistic regression models) | Primary: @ week 9 after TA, improved “dry mouth” (H&N 35 Q41) (OR 2.01; 95% CI 1.38–2.64, Secondary: no difference | With a 4-week crossover randomized design between two interventions, TA improved symptom relief: symptomatic effect on chronic xerostomia |
| Lu W et al. [ | TA: 21 SA: 21 | Patient-reported dysphagia through MDADI (total and subscale scores) | Change from baseline to 12 months after RT/6 months after TA (repeated measures mixed model) | Feasibility | Final data analysis (descriptive measures) | Primary: @ 12 months, MDADI scores improved in both groups (+ 7.9 points in TA, 95% CI 0.2–15.6; + 13.9 points in SA, 95% CI 6.4–21.4) without any difference between TA and SA ( | Feasible trial with audit-confirmed high fidelity (96%) of TA and SA protocols; no difference between TA and SA in improving dysphagia-related QoL |
| Garcia MK et al. [ | TA: 112 SA: 115 SC: 112 | Patient-reported xerostomia through Xerostomia Questionnaire (8-item) | 12 months after RT (analysis of covariance; mixed-model analyses of repeated measures) | Incidence of severe xerostomia (XQ > 30) | 12 months after RT (analysis of covariance; mixed-model analyses of repeated measures) | Primary: @ 12 months after RT, improved mean XQ scores when comparing TA vs SC [adjusted least square mean XQ score of 26.6 (SD 17.7) vs 34.8 (SD 18.7), effect size -0.44, Secondary: @ 12 months after RT, less clinically severe xerostomia when comparing TA vs SC (unadjusted mean XQ score of 30 or more in 34.6% vs 55.1% of patients; | Improved patient-reported xerostomia and less severe symptoms: preventive effect of TA on late xerostomia |
TA true acupuncture, SA sham acupuncture, SC standard care, RSFR resting salivary flow rate, SSFR stimulated salivary flow rate, ANOVA analysis of variance, VAS visual analog scale, RT radiotherapy, @ at, XQ xerostomia questionnaire, RR relative risk, QoL quality of life, OR odds ratio, MDADI MD Anderson dysphagia inventory, SD standard deviation